Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight

Oliver C. Watkins; Preben Selvam; Reshma Appukuttan Pillai; Victoria K.B. Cracknell-Hazra; Hannah E.J. Yong; Neha Sharma; Amaury Cazenave-Gassiot; Anne K. Bendt; Keith M. Godfrey; Rohan M. Lewis; Markus R. Wenk; Shiao Yng Chan

doi:10.1038/s41598-022-18309-2

Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental ¹³C-DHA-metabolism, altering their relationships with birthweight

Oliver C. Watkins, Preben Selvam, Reshma Appukuttan Pillai, Victoria K.B. Cracknell-Hazra, Hannah E.J. Yong, Neha Sharma, Amaury Cazenave-Gassiot, Anne K. Bendt, Keith M. Godfrey, Rohan M. Lewis, Markus R. Wenk, Shiao Yng Chan^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with ¹³C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized ¹³C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most ¹³C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased ¹³C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased ¹³C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.

Original language	English
Article number	14895
Journal	Scientific Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41598-022-18309-2
Publication status	Published - Dec 2022
Externally published	Yes

Access to Document

10.1038/s41598-022-18309-2

Cite this

Watkins, O. C., Selvam, P., Pillai, R. A., Cracknell-Hazra, V. K. B., Yong, H. E. J., Sharma, N., Cazenave-Gassiot, A., Bendt, A. K., Godfrey, K. M., Lewis, R. M., Wenk, M. R., & Chan, S. Y. (2022). Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental ¹³C-DHA-metabolism, altering their relationships with birthweight. Scientific Reports, 12(1), Article 14895. https://doi.org/10.1038/s41598-022-18309-2

@article{f00cbabdaf81429a9616a3bc2c5bbfc7,

title = "Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight",

abstract = "Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.",

author = "Watkins, {Oliver C.} and Preben Selvam and Pillai, {Reshma Appukuttan} and Cracknell-Hazra, {Victoria K.B.} and Yong, {Hannah E.J.} and Neha Sharma and Amaury Cazenave-Gassiot and Bendt, {Anne K.} and Godfrey, {Keith M.} and Lewis, {Rohan M.} and Wenk, {Markus R.} and Chan, {Shiao Yng}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41598-022-18309-2",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Watkins, OC, Selvam, P, Pillai, RA, Cracknell-Hazra, VKB, Yong, HEJ, Sharma, N, Cazenave-Gassiot, A, Bendt, AK, Godfrey, KM, Lewis, RM, Wenk, MR & Chan, SY 2022, 'Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental ¹³C-DHA-metabolism, altering their relationships with birthweight', Scientific Reports, vol. 12, no. 1, 14895. https://doi.org/10.1038/s41598-022-18309-2

TY - JOUR

T1 - Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight

AU - Watkins, Oliver C.

AU - Selvam, Preben

AU - Pillai, Reshma Appukuttan

AU - Cracknell-Hazra, Victoria K.B.

AU - Yong, Hannah E.J.

AU - Sharma, Neha

AU - Cazenave-Gassiot, Amaury

AU - Bendt, Anne K.

AU - Godfrey, Keith M.

AU - Lewis, Rohan M.

AU - Wenk, Markus R.

AU - Chan, Shiao Yng

PY - 2022/12

Y1 - 2022/12

N2 - Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.

AB - Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.

UR - http://www.scopus.com/inward/record.url?scp=85137099357&partnerID=8YFLogxK

U2 - 10.1038/s41598-022-18309-2

DO - 10.1038/s41598-022-18309-2

M3 - Article

C2 - 36050341

AN - SCOPUS:85137099357

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 14895

ER -

Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental ¹³C-DHA-metabolism, altering their relationships with birthweight

Abstract

Access to Document

Other files and links

Fingerprint

Cite this